Recent Advances in Understanding Pain Mechanisms Provide Future Directions for Pain Management

Christine Miaskowski

ONF 2004, 31(4), 25-35. DOI: 10.1188/04.ONF.S4.25-35

Purpose/Objectives: To review current knowledge of neurobiologic mechanisms that generate and maintain chronic pain and to explain how they might be applied in targeting treatment of chronic, inflammatory, and neuropathic pain syndromes.

Jump to a section

    References

    American Pain Society. (2003). Chronic pain in America: Roadblocks to relief: Conclusions. Retrieved June 1, 2004, from http://www.ampainsoc.org/whatsnew/conclude_road.htm

    Basbaum, A.I., & Woolf, C.J. (1999). Pain. Current Biology, 9(12), R429-431.

    Bolay, H., & Moskowitz, M.A. (2002). Mechanisms of pain modulation in chronic syndromes. Neurology, 59(5, Suppl. 2), S2-S7.

    Buchner, A., Bias, P., & Lammerich, A. (2003, June). Twice the therapeutic dose oflicofelone—an inhibitor of COX-1, COX-2, and 5-LOX—results in a significantly lower GI ulcer incidence than naproxen in OA patients when administered with or without concomitant low-dose aspirin. Paper presented at the annual meeting of the European League Against Rheumatism, Lisbon, Portugal.

    Caraceni, A., & Portenoy, R.K. (1999). An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain, 82, 263-274.

    CeNeS Pharmaceuticals. (2003). Product pipeline: Postoperative pain. Retrieved June 7, 2004, from http://www.cenes.com

    Costigan, M., & Woolf, C.J. (2002). No DREAM, no pain: Closing the spinal gate. Cell, 108, 297-300.

    Devers, A., & Galer, B.S. (2000). Topical lidocaine patch relieves a variety of neuropathic pain conditions: An open-label study. Clinical Journal of Pain, 16, 205-208.

    Endo Pharmaceuticals Inc. (2000). Lidoderm® (lidocaine patch 5%) [Patient information brochure]. Chadds Ford, PA: Author.

    Galer, B.S., Jensen, M.P., Ma, T., Davies, P.S., & Rowbotham, M.C. (2002). The lidocaine patch 5% effectively treats all neuropathic pain qualities: Results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clinical Journal of Pain, 18, 297-301.

    Galer, B.S., Rowbotham, M.C., Perander, J., & Friedman, E. (1999). Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: Results of an enriched enrollment study. Pain, 80, 533-538.

    Gammaitoni, A.R., Alvarez, N.A., & Galer, B.S. (2002). Pharmacokinetics and safety of continuously applied lidocain patches 5%. American Journal of Health-System Pharmacy, 59, 2215-2220.

    Gammaitoni, A.R., Alvarez, N.A., & Galer, B.S. (2003). Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: A review of the literature. Journal of Clinical Pharmacology, 43, 111-117.

    Gammaitoni, A.R., & Davis, M.W. (2002). Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Annals of Pharmacotherapy, 36, 236-240.

    Gilron, I. (2001). LY-293558. Eli Lilly & Co. Current Opinion in Investigational Drugs, 2, 1273-1275.

    Hale, M., Dvergsten, C., Kurkimilis, E., & Ahdieh. (2003 June). Oxymorphone extended-release (ER) provides equianalgesia at half the dose compared to oxycodone controlled-release (CR) in chronic low back pain: Results of randomized, parallel group, placebo-controlled study. Paper presented at World Congress of the International Society for the Study of Pain, Lisbon, Portugal.

    Harstall, C., & Ospina, M. (2003, June). How prevalent is chronic pain? [Special newsletter]. Pain Clinical Updates, 9(2). Retrieved August 26, 2003, from http://www.iasp-pain.org/pcu03-2.pdf

    Hawkey, C.J., Karateev, D., Codreanu, C., Dobronte, Z., Gomez Reino, J., Hopkinson, N., et al. (2003. June). Improved upper gastrointestinal (UGI) safety and tolerability of a new coxib, COX 189 compared with ibuprofen in osteoarthritis patients. Paper presented at the annual meeting of the European League Against Rheumatism, Lisbon, Portugal.

    Hernandez, M., Tonda, R., Pedreno, W., Arderiu, G., Pino, M., Serradell, M., et al. (2003. June). Evaluation of the effects of licofelone, an inhibitor of COX-1, COX-2, and 5-LOX, on platelet function in an in vitro model of thrombosis with circulating human blood. Paper presented at the annual meeting of the European League Against Rheumatism, Lisbon, Portugal.

    Indelicato, R.A., & Portenoy, R.K. (2002). Opioid rotation in the management of refractory cancer pain. Journal of Clinical Oncology, 20, 348-352.

    Ji, R.R., & Woolf, C.J. (2001). Neuronal plasticity and signal transduction in nociceptive neurons: Implications for the initiation and maintenance of pathologic pain. Neurobiological Disorders, 8(1), 1-10.

    Julius, D., & Basbaum, A.I. (2001). Molecular mechanisms of nociception. Nature, 413, 203-210.

    Katz, N.P., Gammaitoni, A.R., Davis, M.W., Dworkin, R.H., & the Lidoderm Patch Study Group. (2002). Lidocaine patch 5% reduces pain intensity and interference with quality-of-life in patients with postherpetic neuralgia: An effectiveness trial. Pain Medicine, 3, 324-333.

    Mannion, R.J., & Woolf, C.J. (2000). Pain mechanisms and management: A central perspective. Clinical Journal of Pain, 16(3, Suppl.), S144-S156.

    Mcllwain, H., Burch, F., Frailey, A., Ma, T., & Ahdieh, H. (2003, June). Oxymorphone in extended-release offers long-term safety, effectiveness, and dose stabilization in osteoarthritis pain: Results of a one-year interim report. Paper presented at the World Congress of the International Society for the Study of Pain, Lisbon, Portugal.

    Meier, T., Wasner, G., Faust, M., Kuntzer, T., Ochsner, F., Hueppe, M., et. al. (2003). Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: A randomized, double-blind, placebo-controlled study. Pain, 106, 151-158.

    Miaskowski, C. (2001). Biology of mucosal pain. Journal of the National Cancer Institute Monographs, 29, 37-40.

    Moore, A., Alberighi, D.C., Gitton, X., Sloan, V., & Gimona, A. (2003. June). Responder rate of COX189 in osteoarthritis: A multi-national study. Paper presented at the annual meeting of the European League Against Rheumatism, Lisbon, Portugal.

    Morley, J.S. (1998). Opioid rotation: Does it have a role? Palliative Medicine, 12, 464-466.

    Murray, S.A., Grant, E., Grant, A., & Kendall, M. (2003). Dying from cancer in developed and developing countries: Lessons from two qualitative interview studies of patients and their carers. BMJ, 326, 368.

    Nitu, A.N., Wallihan, R., Skljarevski, V., & Ramadan, N.M. (2003). Emerging trends in the pharmacotherapy of chronic pain. Expert Opinion on Investigational Drugs, 12, 545-559.

    Pavelka, K., Bias, P., Buchner, A., Lammerich, A., & Schulz, U. (2003, June). Licofelone, an inhibitor of COX-1, COX-2, and 5-LOX, is as effective as celecoxib and shows improved tolerability during 12 weeks of treatment in patients with osteoarthritis of the knee. Paper presented at the annual meeting of the European League Against Rheumatism, Lisbon, Portugal.

    Potter, J., Hami, F., Bryan, T., & Quigley, C. (2003). Symptoms in 400 patients referred to palliative care services: Prevalence and patterns. Palliative Medicine, 17, 310-314.

    Regan, J.M, & Peng, P. (2000). Neurophysiology of cancer pain. Cancer Control, 7, 111-119.

    Rowbotham, M.C., Davies, P.S., Verkempinck, C., & Galer, B.S. (1996). Lidocaine patch: Double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain, 65, 39-44.

    Rowbotham, M.C., Twiling, L., Davies, P.S., Reisner, L., Taylor, K., & Mohr, D. (2003). Oral opioid therapy for chronic peripheral and central neuropathic pain. New England Journal of Medicine, 348, 1223-1232.

    Schell, E., Boucher, L., Tamasi, L., Ouellet, J., Moore, A., Lee, A., et al. (2003, June). Long-term efficacy and tolerability oflumiracoxib in osteoarthritis of the knee. Paper presented at the annual meeting of the European League Against Rheumatism, Lisbon, Portugal.

    Scholz, J., & Woolf, C.J. (2002). Can we conquer pain? Nature Neuroscience, 5(Suppl.), 1062-1067.

    Skelly, M.M., & Hawkey, C.J. (2003). COX-LOX inhibition: Current evidence for an emerging new therapy. International Journal of Clinical Practice, 57, 301-304.

    Slatkin, N., Frailey, A., Ma, T., & Ahdieh, H. (2003, June). Oxymorphone extended release offers long-term safety, effectiveness, and dose stabilization in cancer patients: Results of a one-year interim report. Paper presented at the World Congress of the International Society for the Study of Pain, Lisbon, Portugal.

    Stewart, W.F., Ricci, J.A., Chee, E., Morganstein, D., & Lipton, R. (2003). Lost productive time and cost due to common pain conditions in the U.S. workforce. JAMA, 290, 2443-2454.

    Stucky, C.L., Gold, M.S., & Zhang, X. (2001). Mechanisms of pain. Proceedings of the National Academy of Sciences of the United States of America, 98, 11845-11846.

    Subongkot, S., Frame, D., Leslie, W., & Drajer, D. (2003). Selective cyclo-oxygenase-2 inhibition: A target in cancer prevention and treatment. Pharmacotherapy, 23, 9-28.

    U.S. Census Bureau. (2003). State population estimates—Characteristics. Retrieved October 14, 2003, from http://eire.census.gov/popest/data/states/ST-EST2002-ASRO-01.php

    Walters, M.R., Bradford, A.J.P., Fischer, J., & Lees, K.R. (2002). Early clinical experience with the novel NMDA receptor antagonist CNS 5161. British Journal of Clinical Pharmacology, 53, 305-311.

    Woolf, C.J. (1993). The pathophysiology of peripheral neuropathic pain— Abnormal peripheral input and abnormal central processing. Acta Neurochirurgica, 58, 125-130.

    Woolf, C.J., & Decosterd, I. (1999). Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain, 82(Suppl. 6), S141-S147.

    Woolf, C.J., & Mannion, R.J. (1999). Neuropathic pain: Etiology, symptoms, mechanisms, and management. Lancet, 353, 1959-1964.

    Woolf, C.J., & Max, M.B. (2001). Mechanism-based pain diagnosis: Issues for analgesic drug development. Anesthesiology, 95, 241-249.

    Woolf, C.J., & Salter, M.W. (2000). Neuronal plasticity: Increasing the gain in pain. Science, 288, 1765-1768.